Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 25, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 25, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 15, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
Q1 Stability Testing of Drug Substances and Drug Products
Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-23 By FDA
Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Date of authorisation: 20/02/2014, Revision: 24, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
Human medicines European public assessment report (EPAR): Grepid, clopidogrel, Date of authorisation: 27/07/2009, Revision: 29, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
Human medicines European public assessment report (EPAR): Nustendi, bempedoic acid,ezetimibe, Date of authorisation: 27/03/2020, Revision: 8, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
Human medicines European public assessment report (EPAR): Nilemdo, bempedoic acid, Date of authorisation: 01/04/2020, Revision: 9, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
October 10, 2024: Meeting of the Cardiovascular and Renal Drugs Advisory Committee - 10/10/2024
Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-21 By FDA
User Fee Lists
Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-21 By FDA
Counterfeit Medicine
Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-20 By FDA
PREA Non-Compliance Letters
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-06-20 By FDA
Internet Pharmacy Warning Letters
Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-20 By FDA
DG Gel Card 125445, 125449, 125450 - 125457
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-06-20 By FDA
Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine,tozinameran,riltozinameran and tozinameran,famtozinameran and tozinameran,raxtozinameran, Date of authorisation: 21/12/2020, Revision: 54, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-20

Предыдущие записи

Тема: Scaffold от Danny Cooper.